Denali Therapeutics Inc. (DNLI) financials

Denali Therapeutics Inc. (DNLI) revenue, EBIT and EBITDA, earnings per share, free cash flow, margins, debt and shareholders equity — annual and quarterly history, charted from SEC filings. No account needed.

In fiscal 2025, Denali Therapeutics Inc. reported revenue of $0, net income of -$513M, diluted EPS of -$2.97 and free cash flow of -$422M.

Revenue (fiscal 2025)

$0

Net income (fiscal 2025)

-$513M

Diluted EPS (fiscal 2025)

-$2.97

Free cash flow (fiscal 2025)

-$422M

Denali Therapeutics Inc. files with the U.S. Securities and Exchange Commission under CIK 0001714899, classified as Biological Products, (No Diagnostic Substances).

Explore annual and quarterly revenue, earnings, cash flow, margins, debt and equity from SEC filings.